Dalia Elgamal, MSc, PhD

Summary

Dr. El-Gamal is an experimental pharmacologist whose research program focuses on the development and preclinical evaluation of novel therapeutic strategies for lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Dr. El-Gamal's research centers on understanding the interactions between malignant CLL cells and the tumor microenvironment, to uncover disease-specific vulnerabilities, mechanisms of immune dysfunction, and drivers of therapeutic resistance. Her work aims to identify effective single-agent and combination therapies with strong translational potential to improve patient outcomes.

Another key area of interest is the role of the gut microbiome in CLL, with a focus on understanding how microbial communities influence disease biology and treatment response. The ultimate goal of this work is to develop and implement microbiome-targeted interventions that optimize therapeutic efficacy and improve the quality of life of patients with cancer.